Volume : 09, Issue : 05, May – 2022
Title:
70.REVIEW ON MASKED STUDY IN THE FIELD OF CLINICAL TRIALS
Authors :
Akash Pandey, Abhijeet Raghuwanshi*, B. K. Dubey, Deepak Kumar Basedia, Mukesh Kumar Patel
Abstract :
Masked studies, or blinding in clinical trials, are critical for minimizing bias and ensuring the validity of research findings. This review provides an in-depth analysis of masked study designs, including single-blind, double-blind, and triple-blind methodologies. It explores the rationale behind masking, its impact on trial outcomes, and the challenges associated with implementation. The review also discusses various masking strategies, their applications in different therapeutic areas, and the implications for data integrity and participant safety. By examining current practices and emerging trends, this review aims to underscore the importance of masking in enhancing the reliability of clinical trial results and advancing evidence-based medicine.
Keywords: Masked study, Blinding, Clinical trials, Bias reduction, Study design, Data integrity, Therapeutic research
Cite This Article:
Please cite this article in Abhijeet Raghuwanshi et al, Review On Masked Study In The Field Of Clinical Trials, Indo Am. J. P. Sci, 2022; 09 (05).
Number of Downloads : 10
References:
1. Kandi V, Suvvari TK, Vadakedath S, Godishala V: Microbes, clinical trials, drug discovery, and vaccine development: the current perspectives. Borneo J Pharm. 2021, 4:311-23. 10.33084/bjop.v4i4.2571.
2. Purna Singh A, Shahapur PR, Vadakedath S, et al.: Research question, objectives, and endpoints in clinical and oncological research: a comprehensive review. Cureus. 2022, 14:e29575. 10.7759/cureus.29575.
3. Kandi V, Vadakedath S: Clinical research: an overview of study types, designs, and their implications in the public health perspective. Am J Clin Med Res. 2021, 9:36-42. 10.12691/ajcmr-9-2-1 .
4. Kandi V, Vundecode A, Godalwar TR, Dasari S, Vadakedath S, Godishala V: The current perspectives in clinical research: computer-assisted drug designing, ethics, and good clinical practice. Borneo J Pharm. 2022, 5:161-78. . 10.33084/bjop.v5i2.3013.
5. S. B. Throat, S. K. Banerjee, D.D.Gaikwad, S.L.Jadhav, R.M.Thorat,”Clinical trials.”pg. No. 01.
6. Vicki L. Mahan, Clinical Trial Phases,” International Journal of Clinical medicine, 2014, 5, 1374-1385.
7. Rosenthal R. Experimental effects in behavioral research. Appleton -century -crofts, 1966:¹3-4.
8. Karlberg, John Petter Einar ‘Reviewing clinical trial: A guide for the ethics committee ‘ March 2010, pg.no.15.
9. Rosenthal R. Experimental effects in behavioral research. Appleton -century -crofts, 1966:¹3-4.
10. DeMets D, Friedman L, and Furberg C. Fundamentals of Clinical Trials. Springer 4th Edition, 2010; ISBN 978-1-4419- 1585-6.
11. The Lancet (2009). Phase 0 trials: a platform for drug development?. Lancet 2009; 374: 176.
12. CDER. “Exploratory IND Studies”. Guidance for Industry, Investigators, and Reviewers. Food and Drug Administration, 2010.
13. Adil E.S. The Myth of Equipoise in Phase 1 Clinical Trials. Medscape J Med 2008; 10: 254.
14. Gutierrez M. Collyar D. Patient Perspective on phase 0 clinical trials . Clin Cancer Res. 2008 ;14:3689-3691.
15. Chauhan BN ,Modi CM ,Mody SK ,Patel HB , Dudhatra GB ,Kamani DR. Pharmaco -Economics of microdosing clinical trials in drug development process . Int J Anal Pharm Biomed Sci .2012;3:25-26. 16. Kinders RJ, Hollingshead M, Parchment RE . Preclinical modelling of a phase 0 clinical trial protocol. J Clin Oncol 2007 ;25:616s.
16. Baker AF, Dragovich T, Ihle NT ,Williams R, Fenoglio-Preiser C, Powis G . Stability Of Phosphoprotein as a biological marker of tumor Signalling . Clin Cancer Res 2005 ; 11: 4338-40.
17. Abdoler E, Taylor H, Wendler D. The ethics of phase 0 Oncology trial . Clin Cancer Res 2008 ; 14: 3692 -7.
18. Gutierrez M. Collyar D. Patient Perspective on Phase 0 clinical trials. Clin Cancer Res 2008; 14: 3689-91.
19. Store, B.E . (1989) Design and Analysis Of Phase 1 Clinical trials. Biometric, 45,795-798.
20. C. Henon, D. Lissa, X. Paoletti, C. Thibault, C. LeTourneau, E. Lanoy, A. Hollebecque, C. Massard, J.-C. Sorea, S. Postel-VinayPatient-reported tolerability of adverse events in phase 1 trialsESMO Open, 2 (2017), Article e000148.
21. T.J. Hwang, D. Carpenter, J.C. Lauffenburger, B. Wang, J.M. Franklin, A.S. Kesselheim Failure of investigational drugs in late-stage clinical development and publication of trial results JAMA Intern. Med, 176 (2016), pp. 1826-1833
22. J.A. DiMasi, H.G. Grabowski, R.W. Hansen The cost of drug development N. Engl. J. Med., 372 (2015), p. 1972,
23. K.A. Getz Characterizing the real cost of site regulatory compliance Appl. Clin. Trials, 24 (2015) June 1.
24. P.R. Ward, P. Rokkas, C. Cenko, M. Pulvirenti, N. Dean, A.S. Carney, S. Meyer Waiting for” and “waiting in” public and private hospitals: a qualitative study of patient trust in South Australia BMC Health Serv. Res., 17 (2017), p. 333.
25. N.S. Hill, I.R. Preston, K.E. Roberts Patients with pulmonary arterial hypertension in clinical trials Proc. Am. Thorac. Soc., 5 (2008), pp. 603-609.
26. C. Daugherty, M.J. Ratain, E. Grochowski, C. Stocking, E. Kodish, R. Mick, M. Siegler Perceptions of cancer patients and their physicians involved in phase 1 trials J. Clin. Oncol., 13 (1995), pp. 1062-1072.
27. M.N. Fouad, J.Y. Lee, P.J. Catalano, T.M. Vogt, S.Y. Zafar, D.W. West, C. Simon, C.E. Klabunde, K.L. Kahn, J.C. Weeks, C.I. Kiefe Enrollment of patients with lung and colorectal cancers onto clinical trials J. Oncol. Pract., 9 (2) (2013), pp. e40-47.
28. M.G. Ory, P.D. Lipman, P.L. Karlen, M.B. Gerety, V.J. Stevens, M.A. Singh, D.M. Buchner, K.B. Schechtman, FICSIT Group Frailty and injuries: cooperative studies of intervention techniques Prev. Sci., 3 (2002), pp. 1-22.
29. H. Petrovitch, R. Byington, G. Bailey, P. Borhani, S. Carmody, L. Goodwin, J. Harrington, H.A. Johnson, P. Johnson, M. Jones Systolic hypertension in the elderly program (SHEP). Part 2: screening and recruitment Hypertension, 17 (1991), pp. II16-23.
30. L.C. Lovato, K. Hill, S. Hertert, D.B. Hunninghake, J.L. Probstfield Recruitment for controlled clinical trials: literature summary and annotated bibliography Contr. Clin. Trials, 18 (1997), pp. 328-352.
31. R.J. Williams, T. Tse, K. DePiazza, D. Zarin Terminated trials in the ClinicalTrials.gov results database: evaluation of availability of primary outcome data and reasons for termination PLoS One, 10 (2015) Article e0127242.
32. Satoskar, R. S., Bhandar, S. D., Ainapure, S. S., Pharmacology and Pharmacotherapeutic. 8th ed, Popular Prakashan, Mumbai, 2003, 64.